Skip to main content
SpringerLink
Log in

Lipids, lipoproteins, and coronary heart disease: Implications for antihypertensive therapy

  • Hypertension
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

There is now considerable evidence that treatment of abnormalities of lipids and lipoproteins reduces the incidence of coronary heart disease (CHD). Treatment of hypertension, another major cardiovascular risk factor, has not been shown to have the same impact on CHD. Possible explanations for this are that cardiovascular risk factors may occur in combination in an individual or that therapy for hypertension has adversely affected one or several of the other risk factors for CHD, thereby effuetting the benefit gained by lowering blood pressure.

This article reviews the relationship between lipids, lipoproteins, and coronary heart disease, and the impact of cholesterol lowering on CHD. The evidence that antihypertensive drugs are associated with lipid and lipoprotein abnormalities is introduced by a critical appraisal of the several studies for such evidence. Implications for the treatment of the hypertensive patient are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brown MS, Goldstein JL, Receptor-mediated control of cholesterol metabolism, Science 1976;191:150–154.

    Google Scholar 

  2. Sudhof TC, Goldstein JL, Brown MS, et al. The LDL receptor gene: A mosaic of exons shared with different proteins. Science 1985;228:815–822.

    Google Scholar 

  3. Grundy SM. Cholesterol and coronary heart disease—a new era. JAMA 1986;256:2849–2858.

    Google Scholar 

  4. Gordon T, Gastelli WP, Hiortiand MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–714.

    Google Scholar 

  5. Reichl D, Miller NE. The anatomy and physiology of reverse cholesterol transport. Clin Sci 1986;70:221–231.

    Google Scholar 

  6. Castelli WP. The triglyceride issue: A view from Framingham. Am Heart J 1986;112:432–437.

    Google Scholar 

  7. Cambien F, Jacqueson A, Richard JL et al. Am J Epidemiol 1986;124:624–632.

    Google Scholar 

  8. Consensus Conference: Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080–2086.

    Google Scholar 

  9. Study Group of the European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 1987;8:77–88.

    Google Scholar 

  10. Martin MJ, Hulley SB, Browner WS et al. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361,662 men. Lancet 1986;2:933–936.

    Google Scholar 

  11. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 1987;257:2176–2180.

    Google Scholar 

  12. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987;317:1237–1245.

    Google Scholar 

  13. Oliver MF, Heady JA, Morris JN et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: A report from the Committee of Principal Investigators. Br Heart J 1978;40:1069–1118.

    Google Scholar 

  14. Committee of Principal Investigators WHO. Co-operative trial of primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol. Trial mortality follow-up. Lancet 1984;2:600–604.

    Google Scholar 

  15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results I and II. JAMA 1984;251:351–374.

    Google Scholar 

  16. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1986;257:3233–3240.

    Google Scholar 

  17. Illingworth DR. Lipid-lowering drugs: An overview of indications and optimum therapeutic use. Drugs 1987;33:259–279.

    Google Scholar 

  18. Brown MS, Goldstein JL. Drugs used in the treatment of hyperlipidaemic. In: GoodmanAG, GoodmanLSD, RallTW, MuradF eds. The pharmacological basis of therapeutics, 7th ed New York: McMillan, 1985.

    Google Scholar 

  19. Rose G. Review of primary prevention trials. Am Heart J 1987;114:1013.

    Google Scholar 

  20. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202:116.

    Google Scholar 

  21. Veterans Administration Cooperative Study Group in Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143.

    Google Scholar 

  22. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562.

    Google Scholar 

  23. Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980;1:1261.

    Google Scholar 

  24. Helgeland A. Treatment of mild hypertension: A five-year controlled drug trial. The Oslo study. Am J Med 1980; 69:725.

    Google Scholar 

  25. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985;291:97.

    Google Scholar 

  26. Amery A, Birkenhager W, Brixko P et al. Mortality and morbidity from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349.

    Google Scholar 

  27. Multiple Risk Factor Intervention Trial Research Group. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six year intervention results for men in special intervention and usual care groups. Arch Intern Med 1985;145:1191–1199.

    Google Scholar 

  28. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hyperten 1985; 3:297–306.

    Google Scholar 

  29. Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. Drugs 1986;32:260–278, 335–357.

    Google Scholar 

  30. Lehtonen A. Effects of beta-blockers on plasma lipids during antihypertensive therapy. J Cardiovasc Pharmacol 1985; 7:S110-S114.

    Google Scholar 

  31. van Brummelen P. The relevance of intrinsic sympathomimetic activity for beta-blocker induced changes in plasma lipids. J Cardiovasc Pharmacol 1983;5:S51-S55.

    Google Scholar 

  32. MacMahon SW, MacDonald GJ. Antihypertensive treatment and plasma lipoprotein levels: The associations in data from a population study. Am J Med 1986;80(Suppl 2A):20–47.

    Google Scholar 

  33. MacMahon SW, Cutler JA, Furberg CD, Payne CH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: A review of randomised controlled trials. Prog Cardiovasc Dis 1986;29 (Suppl 1):99–118.

    Google Scholar 

  34. Ames RP. The influence of non-beta-blocking drugs on the lipid profile: Are diuretics outclassed as initial therapy for hypertension? Am Heart J 1987;114:998.

    Google Scholar 

  35. McKenny JM, Goodman RP, Wright JJ et al. The effects of low-dose hydrochlorothiazide on blood pressure, serum potassium and lipoproteins. Pharmacology 1986;6:179–184.

    Google Scholar 

  36. Grimnm RH, Leo AS, Hunninghake DB et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med 1981;94:7–11.

    Google Scholar 

  37. Weinberger MH. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1982;14(Suppl):127–132.

    Google Scholar 

  38. Freis ED, Matersoin BJ. Short-term versus long-term changes in serum cholesterol with thiazide diuretics alone. Lancet 1984;1:1414.

    Google Scholar 

  39. Boehringer K, Weidmann P, Mordasini R et al. Menopausal dependent plasma lipoprotein alterations in diuretic-treated women. Ann Intern Med 1982;97:206–209.

    Google Scholar 

  40. Weidmann P, Bianchetti M, Mordasini R. Effects of indapamide and various diuretics alone or combined with beta-blockers on serum lipoproteins. Curr Med Res Opinion 1983;8:123–134.

    Google Scholar 

  41. Northcote RJ, Ballantyne D. Beta-receptor blockade and plasma lipoproteins. Comparisons of the effects of propranolol and pindolol on lipoproteins including high-density lipoprotein subfractions. Clin Sci 1987;72:549–556.

    Google Scholar 

  42. Day JL, Metcalfe J, Simpson N, Lowenthal L. Adrenergic mechanisms in the control of plasma lipids in man. Br Med J 1982;284:1145–1148.

    Google Scholar 

  43. Sacks FM, Dzau VJ. Adrenergic effects as plasma lipoprotein metabolism speculation on mechanisms of action. Am J Med 1986;80(Suppl 2A):71–81.

    Google Scholar 

  44. Barboriak JJ, Friedberg HD. Propranolol and hypertriglyceridaemia. Atherosclerosis 1973;17:31–35.

    Google Scholar 

  45. Leren P, Foss PO, Helgeland A, Hjermaqnn I, Holme I et al. Effects of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 1980;2:4–7.

    Google Scholar 

  46. Singleton W, Taylor CR. Effect of trimazosin on serum lipid profilea in hypertensive patients. Am Heart J 1983;106: 1265–1268.

    Google Scholar 

  47. Lehtonen A, Himatton P, Saraste M, Nittymaki K, Marniemi J. Double-blind comparison of the effects of long term treatment with doxazosin or atenolol on serum lipoproteins. Br J Clin Pharmacol 1986;21:775–815.

    Google Scholar 

  48. Martinez TLR, Auriemo CRC, Machado AMO, Cunha MA et al. Effects of indoramin and metopralol on plasma lipids and lipoproteins. J Cardiovasc Pharmacol 1986;8(Suppl 2):533–555.

    Google Scholar 

  49. Hylander B, Eliassen K, Nilssen Ehle PO, Rosaner S. Effects of long term therapy with labetolol on lipoprotein metabolism in patients with mild hypertension. Acta Med Scand 1985;218:51–54.

    Google Scholar 

  50. Trost BN, Weldmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: A review. J Hyperten 1987;5(Suppl 4):S81-S104.

    Google Scholar 

  51. Marotta T, Rubba P, Pasanisi F et al. Effect of nitrendipine on glucose and lipid metabolism. III European Meeting on Hypertension, 1987, Abstract 349.

  52. Kannel WB. Hypertension and other risk factors in coronary heart disease. Am Heart J 1987;114:918–925.

    Google Scholar 

  53. Tyroler HA. Review of lipid lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987; 76:515–522.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Therapeutics, Charing Cross and Westminater Medical School, St. Stephen's Hospital, London, U.K.

    M. D. Feher

  2. Department of Medicine, University College and Middlesex School of Medicine, The Rayne Institute, London, U.K.

    D. J. Betteridge

Authors
  1. M. D. Feher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. J. Betteridge
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feher, M.D., Betteridge, D.J. Lipids, lipoproteins, and coronary heart disease: Implications for antihypertensive therapy. Cardiovasc Drug Ther 3 (Suppl 1), 333–340 (1989). https://doi.org/10.1007/BF00148479

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00148479

Key Words

Search

Navigation